Adquisición vacuna frente al virus respiratorio sincitial (VRS)

Secretaría General de la Consejería de Sanidad de la Junta de Comunidades de Castilla-La Mancha·Toledo, Spain·EUR 7.9M·Expired · Jul 10, 2026·Open·Supplies

Zarejestruj się, aby zapisać Open documents

High valueStructured notice only

Oryginalny tytuł ogłoszenia

Spain – Vaccines – Adquisición vacuna frente al virus respiratorio sincitial (VRS)

70/100

Ocena szansy

Needs reviewMedium complexity

SuppliesExpired

Skąd ta ocena?

Szansa

70 / 100

Złożoność

60 / 100

Czynniki ryzyka

Structured data indicates EU-funded, but XML notice states 'no-eu-funds'. This could affect contract terms or condition...

No procurement documents were analyzed; essential details (e.g., technical specs, contract terms) are unknown.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

Description
Industries & Services
Capabilities
Market & Experience
Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

EUR 7.9M estimated value
Supplies contract
1 lot
Duration 13 MONTH
Supply of VRS vaccine for adult and high-risk populations
Duration of 13 months

Pokaż pełne podsumowanie

Open tender for the supply of a vaccine against Respiratory Syncytial Virus (VRS) for adult and high-risk populations in Castilla-La Mancha, Spain. Single lot, estimated value €7,920,000, 13-month contract. EU-funded according to structured data, but XML notice indicates no EU funds. Award criteria 60% quality, 40% price. Selection criteria include annual turnover and references. Deadline 10 July 2026.

Ryzyka

Structured data indicates EU-funded, but XML notice states 'no-eu-funds'. This could affect contract terms or condition...

No procurement documents were analyzed; essential details (e.g., technical specs, contract terms) are unknown.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Eligibility

Annual turnover and references required for eligibility

Administrative

Open procedure, electronic submission required
Language: Spanish

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

Quality: Co-administration with flu and COVID-19 vaccines (8 points) — 8%Quality: Maximum demonstrated immunity duration (12 points) — 12%Quality: Efficacy evidence in vulnerable subgroups (12 points) — 12%Quality: Level of clinical efficacy evidence (12 points) — 12%Price: Economic offer (40 points) — 40%Quality: Validity period (10 points) — 10%Quality: Pharmaceutical presentation (2 points) — 2%Quality: Replacement for cold chain breakage (4 points) — 4%